Podcasts about Genome

AI Daily Rundown: September 19th, 2025: Your daily briefing on the real world business impact of AIHello AI Unraveled listeners, and welcome to today's news where we cut through the hype to find the real-world business impact of AI.Today's Headlines:

Ulrike Granögger is a researcher and lecturer passionate about the convergence of science with spirituality. Ulrike's background is as a linguist, however, she has been one of the foremost exponents of ‘alternative' or ‘future' science. With the attitude of a noble journalist, she has met, interviewed and understood the work of many scientists at the fringe of their profession. This has allowed her to explore ideas of quantum biology and the holographic nature of genetic material. Ulrike also contributes to Catherine Austin Fitts' Solari Report, where she regularly writes and speaks about topics under the umbrella of ‘future science'.Please consider subscribing to my Substack where I share my detailed thoughts and insights on my podcast topics and beyond. This is the best way to support me and the podcast. https://ricciflow.substack.com/An additional solo podcast to accompany this conversation is available on my Substack if you'd like to go deeper into this topic: https://ricciflow.substack.com/p/ulrike-granoggerFollow UlrikeThe Solari ReportWave Genome DocumentaryPeter Gariaev's PublicationsPeter Gariaev TributeInstitute of LinguisticsReflections on Life and Intelligence on Planet EarthFollow MeWebsiteSubstackConsultationInstagramYoutubeTwitter/XSpotifyAppleLinktree

The study of DNA damage has broad relevance to human pathophysiology with its involvement in birth defects, cancer, premature aging syndromes, and certain neurologic disorders. Single strand breaks (SSBs) are among the most common form of endogenous DNA damage. Here we will describe mechanisms by which SSBs threaten genome integrity in mitotic and post-mitotic cells. If they are not resolved in a timely manner, SSBs can derail passing replication forks converting them to toxic double strand breaks (DSBs). These so called “collapsed forks” arise spontaneously in every S phase and are believed to be the primary physiological trigger of homologous recombination. We will describe a recent study using the CRISPR/Cas9 nicking enzymes to examine the interaction of the human replication machinery with SSBs. We combine direct analyses of DNA end structures at sites of DNA nick-induced fork collapse with detailed mapping of repair factor binding to establish a comprehensive high-resolution view of how replication-coupled DSBs are generated, processed, and repaired. Our recent studies have also identified unexpected high levels of single strand breakage in neurons, which arise during metabolic processes intrinsic to neuronal development, differentiation, and maintenance. The source of this “programmed” DNA breakage in neurons will be described, and how this physiological process can be corrupted to drive neurodegenerative diseases and neurotoxicity after chemotherapy. Through these basic research efforts, we hope to identify vulnerabilities specific to cancer cells and to discover mechanisms underpinning chemotherapy-induced neurotoxities, which may contribute to new preventive and treatment strategies.

My guest is Michael Snyder, PhD, professor of genetics at Stanford and an expert in understanding why people respond differently to various foods, supplements, behavioral and prescription interventions. We discuss how to optimize your health and lifespan according to what type of glucose responder you are, which genes you express, your lifestyle and other factors. Dr. Snyder also explains the key ages when you need to be particularly mindful about following certain health practices. We also discuss how people respond in opposite ways to different fiber types. This episode ought to be of interest and use to anyone seeking to understand their unique biological needs and how to go about meeting those needs. Sponsors AGZ by AG1: https://drinkag1.com/huberman Wealthfront*: https://wealthfront.com/huberman David: https://davidprotein.com/huberman Eight Sleep: https://eightsleep.com/huberman Function: https://functionhealth.com/huberman *This experience may not be representative of the experience of other clients of Wealthfront, and there is no guarantee that all clients will have similar experiences. Cash Account is offered by Wealthfront Brokerage LLC, Member FINRA/SIPC. The Annual Percentage Yield (“APY”) on cash deposits as of December 27,‬ 2024, is representative, subject to change, and requires no minimum. Funds in the Cash Account are swept to partner banks where they earn the variable‭ APY. Promo terms and FDIC coverage conditions apply. Same-day withdrawal or instant payment transfers may be limited by destination institutions, daily transaction caps, and by participating entities such as Wells Fargo, the RTP® Network, and FedNow® Service. New Cash Account deposits are subject to a 2-4 day holding period before becoming available for transfer. Timestamps 00:00 Michael Snyder 03:33 Healthy Glucose Range, Continuous Glucose Monitors CGM, Hemoglobin A1c 09:02 Individual Variability & Food Choice, Glucose Spikes & Sleepiness 12:18 Sponsors: AGZ by AG1 & Wealthfront 15:16 Glucose Spikes, Tools: Post-Meal Brisk Walk; Soleus “Push-Ups”; Exercise Snacks 21:06 Glucose Dysregulation, Diabetes & Sub-Phenotypes, Tool: Larger Morning Meal 28:34 Exercise Timing, Muscle Insulin Resistance 30:49 Diabetes Subtyping, Weight, Glucose Control; Incretins 35:41 GLP-1 Agonists, Diabetes, Tool: Muscle Maintenance & Resistance Training 38:40 Metformin, Berberine, Headaches 41:01 GLP-1 Agonists, Cognition, Longevity, Tool: Habits Support Medication; Cycling 47:41 Subcutaneous vs Visceral Fat, Organ Stress 49:10 Sponsors: David & Eight Sleep 51:58 Meal Timing & Sleep, Tools: Post-Dinner Walk, Routines, Bedtime Consistency 57:16 Microbiome, Immune System & Gut; Diet & Individual Variability 1:02:52 Fiber Types, Cholesterol & Glucose, Polyphenols 1:09:50 Food As Medicine; Fiber, Microbiome & Individual Variability; Probiotics 1:18:48 Sponsor: Function 1:20:35 Profiling Healthy Individuals, Genomes, Wearables 1:26:31 Whole-Body MRIs, Nodules, Healthy Baseline, Early Diagnosis 1:34:07 Sensors, CGM, Sleep, Heart Rate Variability HRV, Tools: Mindset Effects, Increase REM 1:39:30 HRV, Sleep, Exercise, Tool: Long Exhales; Next-Day Excitement & Sleep 1:42:48 Organ Aging, “Ageotypes”; Biological Age vs Chronological Age 1:49:41 Longevity, Health Span, Genetics, Blue Zones 1:52:19 Epigenetics, Viral Infection & Disease 1:58:54 ALS, Heritability; Neuroprotection, Nicotine 2:03:47 Air Quality, Allergies, DEET & Pesticides, Inflammation, Mold; Microplastics 2:15:02 Single-Drop Blood Test & Biomarkers, Wearables, Observational Trials 2:20:33 Acupuncture, Blood Pressure 2:26:40 Immersive Events & Mental Health Benefits 2:34:59 Data, Nutrition & Lifestyle; Siloed Health Care vs Personalized Medicine 2:43:06 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Social Media, Neural Network Newsletter Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Epigenetics Podcast, we talked with Luca Magnani from Institute of Cancer Research and UNIMI in Milan about his work on epigenetic mechanisms of drug resistance and cancer cell dormancy in breast cancer. We start the interview by putting our focus on his significant contributions to the understanding of estrogen receptor-positive breast cancer. In a foundational study from 2013, Professor Magnani and his colleagues illuminated the role of genome-wide reprogramming of the chromatin landscape in conferring resistance to endocrine therapy. This research marked a departure from a purely genetic mutation paradigm, proposing instead that epigenetic modifications play a pivotal role in the development of drug resistance. A fascinating part of our conversation centers on the role of pioneer transcription factors, particularly PBX1, in regulating the estrogen receptor's transcriptional response. Professor Magnani explains how PBX1, typically associated with hematopoietic development, influences estrogen receptor activity, thereby shaping the cancer cell's fate and response to treatment. Continuing our exploration, we discuss the critical distinctions between primary and metastatic breast cancer through the lens of epigenetic reprogramming. By analyzing samples from women with breast cancer, Professor Magnani's work identifies specific enhancer usage that marks the transition to a drug-resistant state which was a breakthrough in linking epigenetic alterations to real-world patient outcomes. He emphasizes that the reliance on genetic mutations alone does not adequately explain the mechanisms of drug resistance, pushing the field to consider the epigenetic landscape more deeply. Our conversation also touches on the evolution of experimental techniques. Professor Magnani shares insights into the transition from traditional ChIP-seq methods to CUT&RUN, demonstrating the need for techniques that cater to the limited material available from clinical samples. This adaptability mirrors the dynamic nature of cancer itself, as cells continuously evolve under therapeutic pressure. As we traverse through the complexities of dormancy and reactivation in cancer cells, Professor Magnani enlightens us on the unpredictable nature of tumor behavior. He describes how cancer cells can enter dormant states and how their awakening is influenced by environmental factors, akin to an evolutionary response to stressors, thus revealing the intricate balance between survival and proliferation. In the latter part of the episode, we explore Professor Magnani's vision for the future of breast cancer research, which includes the need for better animal models that mimic human disease. His pursuit of understanding estrogen receptor behavior both in healthy and cancerous cells reflects a holistic approach to cancer biology, aiming to decipher the transition from normal tissue to malignancy.   References Magnani, L., Stoeck, A., Zhang, X., Lánczky, A., Mirabella, A. C., Wang, T. L., Gyorffy, B., & Lupien, M. (2013). Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 110(16), E1490–E1499. https://doi.org/10.1073/pnas.1219992110 Nguyen, V. T., Barozzi, I., Faronato, M., Lombardo, Y., Steel, J. H., Patel, N., Darbre, P., Castellano, L., Győrffy, B., Woodley, L., Meira, A., Patten, D. K., Vircillo, V., Periyasamy, M., Ali, S., Frige, G., Minucci, S., Coombes, R. C., & Magnani, L. (2015). Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nature communications, 6, 10044. https://doi.org/10.1038/ncomms10044 Patten, D. K., Corleone, G., & Magnani, L. (2018). Chromatin Immunoprecipitation and High-Throughput Sequencing (ChIP-Seq): Tips and Tricks Regarding the Laboratory Protocol and Initial Downstream Data Analysis. Methods in molecular biology (Clifton, N.J.), 1767, 271–288. https://doi.org/10.1007/978-1-4939-7774-1_15   Related Episodes Enhancers and Chromatin Remodeling in Mammary Gland Development (Camila dos Santos) Contribution of Estrogen Receptor to Breast Cancer Progression (Jason Carroll) Circulating Epigenetic Biomarkers in Cancer (Charlotte Proudhon)   Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

AI and genetic medicine are converging to transform how we diagnose, treat, and prevent disease. Gene Yeo, Ph.D., unites RNA biology with artificial intelligence to speed the path from genome sequencing to personalized RNA therapeutics. Advances in sequencing have reduced costs dramatically, making interpretation and translation into treatments the real challenge. Using deep learning and large datasets of RNA-binding proteins, Yeo predicts disease vulnerabilities and identifies therapeutic targets, including in neurodegeneration and muscular diseases. Alexis Komor, Ph.D., focuses on DNA, explaining human genetic variation—particularly single-nucleotide variants—and how genome editing technologies like CRISPR can target them. She highlights strategies to correct harmful mutations and explores precise, programmable interventions. Together, their research drives discovery and enables more effective, personalized therapies. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40459]

The first complete draft of the human genome was published back in 2003. Since then, researchers have worked both to improve the accuracy of human genetic data, and to expand its diversity, looking at the genetics of people from many different backgrounds. Three genetics experts join Host Ira Flatow to talk about a recent close examination of the genomes of 65 individuals from around the world, and how it may help researchers get a better understanding of genomic functioning and diversity.Guests:Dr. Christine Beck is an associate professor of genetics and genome sciences in the University of Connecticut Health Center and the Jackson Laboratory.Dr. Glennis Logsdon is an assistant professor of genetics and a core member of the Epigenetics Institute at the University of Pennsylvania.Dr. Adam Philippy is a Senior Investigator in the Center for Genomics and Data Science Research at the National Human Genome Research Institute at the NIH.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Optical Genome Mapping (OGM) stellt unser Erbgut ähnlich wie einen Barcode dar – und macht strukturelle Veränderungen sichtbar, die andere Methoden oft übersehen. In dieser Folge erklärt Dr. Kornelia Neveling, Radboud University Medical Center, wie OGM funktioniert, wo es bereits in der Diagnostik eingesetzt wird und warum es gerade bei Leukämien und Seltenen Erkrankungen neue Antworten liefert. Außerdem sprechen wir über typische Anwendungen, Fallbeispiele und die Zukunft dieser Technologie in der klinischen Praxis.

In our final episode of The Road to Genome season 5, we speak to the CEO of Genomics England Dr Richard Scott about the work of Genomics England, the creation of the Generation Study, and having the tough discussions to drive the future of genomics.Dr Richard Scott joined Genomics England in 2015. He is also a Consultant and Honorary Senior Lecturer in Clinical Genetics at Great Ormond Street Hospital for Children and the UCL Institute of Child Health where his practice focuses on diagnosing children with rare multisystem disorders.

Jon wants to know, how do the cells in the human body, in all their variety, differ at the genetic level? James Tytko took his query on... Like this podcast? Please help us by supporting the Naked Scientists

In this episode of the Epigenetics Podcast, we talked with Dr. Joseph Ecker from the Salk Institute about his work on high-resolution genome-wide mapping technologies, specifically how the regulation of gene expression is influenced by DNA methylation, chromatin accessibility, and non-coding RNAs across various cell types and developmental stages. During our conversation, we delve into Dr. Ecker's contributions to the characterization of the genome of Arabidopsis thaliana, a project pivotal in the plant genomics field, where he collaborated on the early sequencing efforts that dramatically outpaced expectations. He highlights the technological advancements that enabled such efficient sequencing and how this foundational work opened new avenues for exploring transcriptional activity. We also discuss Dr. Ecker's pivotal work on the comprehensive DNA methylation map of Arabidopsis, which he developed in collaboration with other researchers. This groundbreaking study established the links between methylation patterns and gene expression, paving the way for further research into how these epigenetic marks influence over gene regulation. He elaborates on the significance of transitioning from traditional methods to more sophisticated techniques, such as RNA-seq, and the lessons learned from sequencing projects that have since been applied to human biology. Dr. Ecker's transition to studying human cells is further explored as he discusses the profiling of DNA methylation in induced pluripotent stem cells (iPSCs), revealing how epigenetic memory can influence cellular differentiation and development. He underscores the importance of understanding these methylation patterns, particularly as they relate to conditions like Alzheimer's disease and stem cell biology, where he examines potential applications of his findings in medical research. As our conversation progresses, we touch upon Dr. Ecker's ongoing projects that utilize advanced multi-omic techniques to investigate the epigenomes of the human brain, focusing on how DNA methylation and gene expression change with age and in the context of neurodegenerative diseases. He details the collaboration efforts with various consortia aimed at cataloging gene regulatory networks and understanding the complex interactions that take place within the brain throughout different life stages.   References Mozo T, Dewar K, Dunn P, Ecker JR, Fischer S, Kloska S, Lehrach H, Marra M, Martienssen R, Meier-Ewert S, Altmann T. A complete BAC-based physical map of the Arabidopsis thaliana genome. Nat Genet. 1999 Jul;22(3):271-5. doi: 10.1038/10334. PMID: 10391215. Zhang X, Yazaki J, Sundaresan A, Cokus S, Chan SW, Chen H, Henderson IR, Shinn P, Pellegrini M, Jacobsen SE, Ecker JR. Genome-wide high-resolution mapping and functional analysis of DNA methylation in arabidopsis. Cell. 2006 Sep 22;126(6):1189-201. doi: 10.1016/j.cell.2006.08.003. Epub 2006 Aug 31. PMID: 16949657. Lister R, O'Malley RC, Tonti-Filippini J, Gregory BD, Berry CC, Millar AH, Ecker JR. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell. 2008 May 2;133(3):523-36. doi: 10.1016/j.cell.2008.03.029. PMID: 18423832; PMCID: PMC2723732. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, Edsall L, Antosiewicz-Bourget J, Stewart R, Ruotti V, Millar AH, Thomson JA, Ren B, Ecker JR. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009 Nov 19;462(7271):315-22. doi: 10.1038/nature08514. Epub 2009 Oct 14. PMID: 19829295; PMCID: PMC2857523. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011 Mar 3;471(7336):68-73. doi: 10.1038/nature09798. Epub 2011 Feb 2. Erratum in: Nature. 2014 Oct 2;514(7520):126. PMID: 21289626; PMCID: PMC3100360.   Related Episodes Epigenetic Reprogramming During Mammalian Development (Wolf Reik) Single Cell Epigenomics in Neuronal Development (Tim Petros)   Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

**

In this interview, Lord Ridley examines the pervasive pessimism shaping climate narratives within the media and academia. He addresses the transformative power of affordable energy for developing nations and warns against beliefs about energy and climate that ignore the needs of those in poverty.Ridley also criticises the politicisation of science in both climate and Covid modelling, arguing it distorts evidence, suppresses debate, and drives harmful policies that undermine economic and social progress. He urges a shift towards optimism driven by innovation and evidence, advocating for rational energy policies and transparent scientific inquiry to foster prosperity and address global challenges effectively.Lord Matthew Ridley is a British science writer, journalist, and hereditary peer with a background in zoology and a distinguished career spanning academia, business, and public service. He holds a DPhil from Oxford University and is best known for his best-selling books on science, economics, and human progress, including The Rational Optimist, Genome, and How Innovation Works. Ridley served as chairman of the UK-based bank Northern Rock and was a member of the House of Lords from 2013 to 2021, where he contributed to debates on science, technology, and innovation policy. This interview was filmed at ARC London 2025.

First up on the podcast, Newsletter Editor Christie Wilcox joins host Sarah Crespi to celebrate the 2-year anniversary of ScienceAdviser with many stories about the amazing water bear. They also discuss links between climate change, melting glaciers, and earthquakes in the Alps, as well as what is probably the first edible laser.   Next on the show, freelance producer Elah Feder talks with Tatiana Feuerborn,  a postdoctoral fellow in the cancer genetics and comparative genomics branch of the National Institutes of Health, about the evolutionary history of the Greenland sled dog. Her team's work sequencing 98 genomes from modern and ancient sled dogs reveals the canine's current diversity and suggests approaches for conservation.   This week's episode was produced with help from Podigy.   About the Science Podcast   Authors: Sarah Crespi; Elah Feder; Christie Wilcox  Learn more about your ad choices. Visit megaphone.fm/adchoices

First up on the podcast, Newsletter Editor Christie Wilcox joins host Sarah Crespi to celebrate the 2-year anniversary of ScienceAdviser with many stories about the amazing water bear. They also discuss links between climate change, melting glaciers, and earthquakes in the Alps, as well as what is probably the first edible laser.   Next on the show, freelance producer Elah Feder talks with Tatiana Feuerborn,  a postdoctoral fellow in the cancer genetics and comparative genomics branch of the National Institutes of Health, about the evolutionary history of the Greenland sled dog. Her team's work sequencing 98 genomes from modern and ancient sled dogs reveals the canine's current diversity and suggests approaches for conservation.   This week's episode was produced with help from Podigy.   About the Science Podcast   Authors: Sarah Crespi; Elah Feder; Christie Wilcox  Learn more about your ad choices. Visit megaphone.fm/adchoices

Join us for an exciting episode of The Edge of Show, live from Proof of Talk in Paris! In this episode, we dive deep into the intersection of blockchain technology and genetics with Aldo de Pape CEO and co-founder of Genomes.io. Discover how Genomes.io is revolutionizing the way we handle genetic data, ensuring safety and privacy while enabling scientific progress.Next, Joshua Field tells us how BitTensor is integrating blockchain with AI, creating decentralized networks for intelligence, and the implications of this technology for the future.Additionally, we hear from Arthur Breitman, co-founder of Tezos, as he discusses the evolution of the Tezos ecosystem, the importance of governance in blockchain, and their latest ventures into tokenizing commodities like uranium.Tune in to hear about:The role of blockchain in genetics and data privacyThe future of decentralized AI with BitTensorTezos' innovative projects and aspirations in the blockchain spaceInsights on the challenges and opportunities in the crypto industryWhether you're a blockchain enthusiast, a tech innovator, or just curious about the future of digital technology, this episode is packed with valuable insights and thought-provoking discussions. Don't miss it!Support us through our Sponsors! ☕

Episode 310 An ancient Egyptian's complete genome has been read for the first time. The DNA of a man who lived in Egypt over 4500 years ago offers a new window into the ancient society and hints at surprising genetic connections with Mesopotamia. Based on forensic analysis of the man's skeleton and preserved images of different Egyptian occupations, the researchers think his most likely occupation was a potter. The team discusses what the breakthrough means for our understanding of early Egypt and even for the origin of writing. Wild orcas, or killer whales, have been seen giving gifts to humans - things like pieces of liver, rays and dead birds. This is the first time these apparent acts of altruism have been documented. Does this prove whales are capable of showing compassion or kindness? Images beamed back from the New Horizons spacecraft, which has left the solar system, have enabled the first test of interstellar navigation. By measuring the distance between two stars that it snapped images of, astronomers have been able to pinpoint its location in the galaxy. And in other interstellar news, we also just spotted an object hurtling towards our solar system. Recently named ‘Atlas', this object will be whizzing by in October, close enough for us to study. Chapters: (00:42) Ancient Egyptian genome sequenced (12:33) Killer whales give humans gifts (18:59) First demonstration of interstellar navigation Hosted by Rowan Hooper and Penny Sarchet, with guests Mike Marshall, Alex Wilkins, Joel Irish and Lori Marino. To read more about these stories, visit https://www.newscientist.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this deeply informative solosode, Dr. Mike Belkowski guides listeners through a comprehensive exploration of mitochondrial function and its profound connection to aging and longevity. Kicking off with a brief reflection on recent guest episodes and a teaser about an upcoming podcast rebrand, Mike then dives into a newly released scientific article from Cell Communication and Signaling titled “Mitochondrial Dysfunction in the Regulation of Aging and Aging-Related Diseases.”   Mike reads and unpacks dense but crucial sections from the paper, including:   The Structure and Function of MitochondriaHe outlines the intricacies of the electron transport chain, supercomplexes, and mitochondrial DNA, emphasizing their roles in energy production, oxidative stress, and aging. Key Cellular Processes Affected by MitochondriaTopics covered include metabolic regulation, calcium and ROS homeostasis, mitochondrial biogenesis, and autophagy, tying them all back to aging and degenerative diseases. Modulating Mitochondrial Function to Slow AgingMike highlights emerging research on mitochondrial nutrients (like CoQ10, alpha-lipoic acid, carnitine), lifestyle interventions (exercise, diet, intermittent fasting), and breakthrough therapies such as mitochondrial transfer and replacement therapies.     He also introduces BioLight's new supplement, BioBlue Fountain of Youth, emphasizing its inclusion of methylene blue or leucomethylene blue, urolithin A, adaptogenic mushrooms, shilajit, and PQQ—all aimed at mitochondrial optimization.   The episode wraps with a powerful message: movement is medicine. Exercise remains the most accessible and potent strategy to boost mitochondrial health naturally. Mike encourages listeners to stay active, get sunlight, engage in red light therapy, and embrace the mitochondrial lifestyle. If you found the information in today's episode particularly interesting and/or compelling, please share it with a family member, friend, colleague and/or anyone that you think could benefit and be illuminated by this knowledge. Sharing is caring :)As always, light up your health! - Key Quotes from Dr. Mike Belkowski: ​​“The mitochondrial space is going to be blown up in the next couple decades for sure… it's going to become a much larger, well-adopted aspect of health and wellness.” ​​“You don't want these dysfunctional cells or these dysfunctional mitochondria to linger around… you want them to be recycled and turned into new, healthy cells.”​“Exercise is the best way to have your endogenous program of mitogenesis running.” - Key points: 00:00 – Introduction: Mitochondrial Focus and Podcast Evolution 02:14 – Podcast Rebrand Announcement & Mitochondrial Mission 03:15 – Review of Article: Mitochondrial Dysfunction in Aging 04:09 – Structure of the Mitochondria: A Deep Dive 06:15 – Electron Transport Chain & Supercomplexes Explained 10:05 – Mitochondrial DNA, Genome, and Gene Expression 11:18 – New BioBlue Supplement Overview and Key Ingredients 14:01 – Mitochondrial Functions: Metabolism, Apoptosis, and Energy 16:29 – Calcium Homeostasis & ROS Generation 20:11 – Antioxidant Defense Systems in Mitochondria 22:15 – Overview of Remaining Sections in the Research Article 25:18 – Targeting Mitochondria to Slow Aging: Introduction 27:13 – Nutrients That Modulate Mitochondrial Function 29:29 – Hormetic Stress, Resilience, and Mitochondrial Biogenesis 31:22 – Calcium Modulators and Mitochondrial Stability 32:01 – Exercise as the Ultimate Mitochondrial Booster 35:03 – Exercise vs. Caloric Restriction in Mitochondrial Health 36:30 – Mitochondria-Supportive Diets and Nutrients 39:12 – Mitochondrial Therapy and Replacement Explained 42:18 – Mitochondrial Replacement for Age-Related Decline 44:17 – Cross-Tissue Mitochondrial Signaling in Aging 45:41 – Translational Research in Mitochondrial Therapeutics 49:08 – Future of Mitochondrial Medicine and Final Thoughts - Save 25% when you Subscribe & Save to a BioBundle!For a BioBundle, you choose: 1.) Any one BioBlue supplement(BioBlue, BioBlue (SR), BioBlue Leuco, BioBlue Calm, BioBlue Capsules or BioBlue Leuco Capsules)2.) Any one BioC60 supplement (Regular or Concentrated)   The BioBundle automatically saves you 15% on both of the supplements you choose. You save an additional 10% by choosing to Subscribe & Save to that BioBundle.   The 25% savings is passed along for every monthly delivery of your BioBundle. No discount code necessary! Discount automatically applied at checkout.   Shop BioBundle by clicking here! - Dr. Mike's #1 recommendations: Water products: Water & Wellness Grounding products: Earthing.com EMF-mitigating products: Somavedic Blue light-blocking glasses: Ra Optics - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram Facebook

On today's episode, hear July's top pistachio article from West Coast Nut on the most comprehensive genome sequence of the pistachio yet, which may provide plant breeders with a genetic roadmap to develop improved cultivars. Read it online at wcngg.com or subscribe for free to receive West Coast Nut in your mailbox. Supporting the People who Support AgricultureThank you to this month's sponsors who makes it possible to get you your daily news. Please feel free to visit their website.2025 Crop Consultant Conference - https://myaglife.com/crop-consultant-conference/

"If you get a new kind of information, suddenly you can do something with it that you couldn't do before at all." In this episode of The Biotech Startups Podcast, Ivan Liachko shares how scientific curiosity and unexpected collaborations took him from DNA replication research in yeast at Cornell to a breakthrough in 3D genome mapping and the founding of Phase Genomics. Embracing Hi-C technology at the University of Washington, Ivan and his team unlocked a new kind of biological information, enabling scientists to assemble genomes and map complex microbial communities and their viruses—transforming what was once impossible into a new standard for genomics. His journey highlights how creativity, collaboration, and seizing serendipitous moments can drive the most impactful scientific innovations.

Today InPerspective with Dr. Harry Reeder June 24, 2025

In this episode Ed discusses the Soybean tentiform leafminer, an emergent insect pest of soybean, with Dr. Bob Koch of the University of Minnesota. Additional Resources Initial detections in soybean:  https://doi.org/10.1093/jipm/pmab038 Laboratory rearing methods:  https://scholar.valpo.edu/tgle/vol57/iss1/9/ Genome and genetic variability among populations: https://doi.org/10.1093/g3journal/jkaf021 Development and longevity:  https://doi.org/10.1093/ee/nvae059 Distinguishing stages and sexes:  https://doi.org/10.1093/aesa/saae040 Insecticide efficacy:  https://doi.org/10.1093/jee/toae249 Host range and host plant resistance:  https://doi.org/10.1093/jee/toaf098 Extension articles: https://extension.umn.edu/soybean-pest-management/soybean-tentiform-leafminer-minnesota-soybean https://blog-crop-news.extension.umn.edu/2024/01/the-soybean-tentiform-leafminer-has.html https://blog-crop-news.extension.umn.edu/2022/09/updates-on-new-leaf-mining-pest-of.html How to cite the podcast: Zaworski, E. (Host) and Koch, R. (Interviewee). S4:E23 (Podcast). Tunnels of Terror: Soybean Tentiform Leafminer. 6/18/25. In I See Dead Plants. Crop Protection Network.   Transcript

In this episode of the Epigenetics Podcast, we talked with Petra Hajkova from the MRC Laboratory of Medical Sciences about her work on epigenetics research on mammalian development, highlighting DNA methylation, histone modifications, and TET enzymes, along with her journey in molecular genetics and future research on epigenetic maintenance. Dr. Hajkova's early work focused on DNA methylation and resulted in innovative collaboration that allowed her to develop bisulfide sequencing techniques. We discuss her transition to the UK, where she began working in Azim Surani's lab at the University of Cambridge. Dr. Hajkova describes the excitement of researching chromatin dynamics in the mouse germline, leading to significant findings published in Nature. Her story highlights the intense yet rewarding nature of postdoctoral research as she navigated the complexities of working with embryos for the first time. As her research progressed, Dr. Hajkova established her own lab at the MRC London Institute of Medical Sciences, where she became a professor in 2017. We delve into her investigations on the differences between embryonic stem cells and embryonic germ cells regarding their distinct developmental origins. Dr. Hajkova outlines the challenges she faced in understanding the mechanisms behind global DNA demethylation in germline cells and the role of hydroxymethylation during early development. The discussion further covers her exciting findings regarding the specific functions of TET enzymes and their regulatory roles in maintaining epigenetic states. We explore her recent research published in Nature, which provides insights into the transition from primordial germ cells to gonocytes, emphasizing the significance of various epigenetic mechanisms in germline development.   References Hajkova P, Ancelin K, Waldmann T, Lacoste N, Lange UC, Cesari F, Lee C, Almouzni G, Schneider R, Surani MA. Chromatin dynamics during epigenetic reprogramming in the mouse germ line. Nature. 2008 Apr 17;452(7189):877-81. doi: 10.1038/nature06714. Epub 2008 Mar 19. PMID: 18354397; PMCID: PMC3847605. Hajkova P, Jeffries SJ, Lee C, Miller N, Jackson SP, Surani MA. Genome-wide reprogramming in the mouse germ line entails the base excision repair pathway. Science. 2010 Jul 2;329(5987):78-82. doi: 10.1126/science.1187945. PMID: 20595612; PMCID: PMC3863715. Hill PWS, Leitch HG, Requena CE, Sun Z, Amouroux R, Roman-Trufero M, Borkowska M, Terragni J, Vaisvila R, Linnett S, Bagci H, Dharmalingham G, Haberle V, Lenhard B, Zheng Y, Pradhan S, Hajkova P. Epigenetic reprogramming enables the transition from primordial germ cell to gonocyte. Nature. 2018 Mar 15;555(7696):392-396. doi: 10.1038/nature25964. Epub 2018 Mar 7. PMID: 29513657; PMCID: PMC5856367. Huang TC, Wang YF, Vazquez-Ferrer E, Theofel I, Requena CE, Hanna CW, Kelsey G, Hajkova P. Sex-specific chromatin remodelling safeguards transcription in germ cells. Nature. 2021 Dec;600(7890):737-742. doi: 10.1038/s41586-021-04208-5. Epub 2021 Dec 8. PMID: 34880491.   Related Episodes Epigenetic Mechanisms of Mammalian Germ Cell Development (Mitinori Saitou) Epigenetic Reprogramming During Mammalian Development (Wolf Reik) DNA Methylation and Mammalian Development (Déborah Bourc'his)   Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

Cutting cysteine =

Welcome to another wide-ranging "Random Show" episode I recorded with my close friend Kevin Rose (digg.com)! We cover dozens of topics: from the cutting edge of health tech to pro-tips for colonoscopies; AI; adventures in Japan and Taiwan seeking out perfect coffee and tea; tips for drinking less alcohol; powerful documentaries like 32 Sounds and books such as Awareness; the unexpected joys and therapeutic benefits of adult Lego; and much, much more.Sponsors:Vanta trusted compliance and security platform: https://vanta.com/tim ($1000 off) Momentous high-quality supplements: https://livemomentous.com/tim (code TIM for up to 35% off)ExpressVPN high-speed, secure, and anonymous VPN service: https://www.expressvpn.com/tim (get 3 or 4 months free on their annual plans)*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, Margaret Atwood, Mark Zuckerberg, Peter Thiel, Dr. Gabor Maté, Anne Lamott, Sarah Silverman, Dr. Andrew Huberman, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Lisa Markowitz currently teaches Introduction to Cultural Anthropology, People and their Food, Anthropology of Latin America, Globalizing Inequalities, Food Justice, and Contemporary Issues in Anthropology, at the University of Louisville. Markowitz's research has focused on inequities in regional and global agrifood systems and popular efforts to transform them. These linked themes have informed her writing and scholarly-civic engagement in Andean South America and the upper U.S. South. She has carried out ethnographic field research in Peru and Bolivia, exploring the situation of peasant farmers and ranchers and their use of communal or collective strategies to improve their production systems and economic bargaining power. This experience led to a long-term interest in Andean food and agriculture as well as an engagement with building equitable food systems in the United States Her work has also addressed the roles of Non-governmental organizations as change agents in South America and the United States. Her most recent project concerns the grocery industry. Michael Perlin: Dr. Michael Perlin teaches Biology 330 Genetics & Molecular Biology, Biol 410 Misuse of Biology in Film and Pop Culture, Biol 542/642 Gene Structure and Function, Biol 416 Biotechnology Methods, and Biol 575/675 Evolution of Genes and Genomes. As a biologist Dr. Michael Perlin investigates the evolution of host/pathogen interactions, primarily at the molecular genetics and biochemical levels. The research in Michael Perlin's lab focuses on the evolution of interactions between pathogens and the hosts on which they cause disease. At present, this work has two main areas of emphasis: fungal/plant interactions and population dynamics of bacteria resistant to antibiotics.

In this episode of Behind the Genes, we explore the hopes, concerns and complex questions raised by the idea of a lifetime genome — a single genomic record used across a person's life to guide healthcare decisions. Drawing on conversations from Genomics England's Public Standing Group on the lifetime genome, our guests explore what it might mean for individuals, families and society to have their genome stored from birth, and how it could transform healthcare. The discussion reflects on the potential for earlier diagnoses, better treatments and long-term prevention, alongside pressing ethical concerns such as data security, consent, and the impact on family dynamics. Participants share their views and discuss the future role of genomic data in medicine, with insights into how trust, equity and public dialogue must shape this evolving field. Our host for this episode, Dr Harriet Etheredge, is joined by Suzalee Blair-Gordon and Gordon Bedford, two members of the Genomics England's Public Standing Group on the lifetime genome, and Suzannah Kinsella, Senior Associate at Hopkins Van Mil, a social sciences research agency that helped to facilitate this work. Together, they consider the broader societal implications of lifetime genomic data, and how public involvement can help guide policy and practice in the UK and beyond. This conversation is part of our ongoing work through the Generation Study, exploring how genomics can be used responsibly and meaningfully from birth onwards. You can listen to some of our Generation Study episodes by following the links below. What can we learn from the Generation Study? How has design research shaped the Generation Study? What do parents want to know about the Generation Study?   "This isn't just a science project, it's about designing a future where everyone feels included and protected. We need more voices, parents, young people, underrepresented communities, to keep shaping it in the right direction."   You can download the transcript, or read it below. Harriet: Welcome to Behind the Genes. Suzalee: I have come to terms with the thought that life is unpredictable and I have already begun to accept any health condition that comes my way. Believe you me, I have been through the stage of denial, and yes, I have frozen upon hearing health diagnoses in the past but now I believe that I am a bit wiser to accept the things that I cannot change and to prepare to face the symptoms of whatever illness I am to be dealt with or to be dealt to me. If the analysis of my genome can help me to prepare, then yes, I am going to welcome this programme with open arms.  Harriet: My name is Harriet Etheredge, and I am the Ethics Lead on the Newborn Genomes Programme here at Genomic England. On today's episode I'm joined by 3 really special guests, Suzalee Blair and Gordon Bedford, who are members of Genomics England's Public Standing Group on Lifetime Genomes, and Suzannah Kinsella, Senior Associate at Hopkins Van Mil, a social sciences research agency that has helped us to facilitate this work.  Today we'll be discussing the concept of the lifetime genome. What do we mean when we say, ‘lifetime genome'? How can we realise the promise of the lifetime genome to benefit people's healthcare whilst at the same time really appreciating and understanding the very real risks associated? How do we collectively navigate ethical issues emerging at this genomic frontier? If you enjoy today's episode, we would really love your support. Please share, like and give us a 5-star rating wherever you listen to your podcasts. And if there's a guest that you'd love to hear on a future episode of Behind the Genes, please contact us on podcast@genomicsengland.co.uk. Let's get on with the show. I'll start off by asking our guests to please introduce yourselves.  Suzalee, over to you.  Suzalee: Thanks, Harriet. So I am a proud mum of two kids, teacher of computing at one of the best academic trusts in the UK, and I am also a sickler, and for those who don't know what that means, I am living with sickle cell disease.  Harriet: Thank you so much, Suzalee. Gordon, over to you.  Gordon: I'm Gordon Bedford, I'm a pharmacist based in The Midlands. I've worked in hospital and community pharmacy. I have a genetic condition, which I won't disclose on the podcast but that was my sort of position coming into this as I'm not a parent of children, but it was coming in from my perspective as a pharmacist professional and as a member of society as well.  Harriet: Thank you so much, Gordon. And, last but certainly not least, Suzannah.  Suzannah: So, yes, Suzannah Kinsella. I am a social researcher at Hopkins Van Mil, and I had the pleasure of facilitating all of the workshops where we gathered together the Public Standing Group and working on reporting the outcome from our discussions, so delighted to be coming in from South London. Harriet: Thank you so much, everyone, and it's such a pleasure to have you here today. So, many regular listeners to Behind the Genes will now that Genomics England is currently undertaking the Generation Study. I'm not going to speak about it in much detail because the Generation Study has already been the subject of several Behind the Genes podcasts and we'll put some links to these in the show notes for this episode. But briefly, the Generation Study aims to analyse whole genomes of 100,000 newborn babies across England, looking for 250 rare conditions. We have a view to getting these children onto treatments earlier and potentially enhancing their lives.  The Generation Study is a research project because we don't know if the application of this technology will work. And as a research project we can also answer other important questions, such as questions about a lifetime genome. When we invite parents to consent to the Generation Study on behalf of their newborn babies, we ask to store babies' genomic data and linked healthcare data in our trusted research environment.  This helps us to further research into genes and health. But a critical question is ‘what do we do with these data long term?' And one of the potential long-term uses of the data is to revisit it and re-analyse it over a person's lifetime.  We could do this at critical transition points in life, like adolescence, early adulthood or older age, with the aim of using the genomic data to really enhance people's health. But this is a very new concept. There's been little work on it internationally, however I am pleased to say that interest seems to be picking up. In the Generation Study, whilst we are at the present time doing no lifetime genomes work, we are looking to explore the benefits, risks and potential uses of the lifetime genome.  This Public Standing Group on lifetime genomes was our first foray into this area.  So, I'd like to start off by inviting Suzannah to please explain a bit more about what the Public Standing Group is, why it was created and how a group like this helps us to generate early deliberation and insight.  Suzannah: So, the first thing I should talk about is who were these 26 people that formed part of this group, and the first thing to say is that they were a wide range of ages and backgrounds from across England, so some from Newcastle, some from London and everywhere in between. And these 26 people all had one thing in common, which is they had all taken part in a previous Genomics England public dialogue, either the whole genome sequencing for newborn screening which took place in 2021, or in a more recent one in about 2022/23 which was looking at what should Genomics England think about in terms of research access to data that's drawn from the Generation Study. So, the great thing was that everybody had already some previous knowledge around genomics, but the concept of a lifetime genome was completely new. So these 26 people met on 5 occasions over the period of 2024, mostly meeting face to face, and really the task that they were given was to look at the lifetime genome and look at it from every angle; consent, use, information sharing and all sorts of other aspects as well. Harriet: Gordon and Suzalee, you were participants in our Public Standing Group, I'd love to hear from you what your roles in the Standing Group were and what you found most interesting, but also for you which bits were the most challenging. Suzalee, shall we start with you? Suzalee: For me the most interesting bits were being able to learn about one's genome and, through Genomics England and their possible use of pharmacogenetics, could determine the specific medication that could be prescribed for a new health condition instead of expensive and possibly tonnes of adverse side effects trial and error medications. Additionally, as a person living with sickle cell disease, I got the chance to share my story and to give voice to people living with the same condition or similar to myself, and how the potential of the genomics newborn programme could help our future generation. There were some tricky bits, and the most challenging bit was to initially discuss and think about the idea of whether or not a parent might choose to know or not to know the potential of their newborn developing or prone to develop a certain condition based on the data received from the programme. My thought went back to when I gave birth to my first child 16 years ago and I was adamant to know if my child would inherit the sickle cell disease, what type, if it would be the trait. In my mind I knew the result, as my haemoglobin is SC and their dad is normal, but I wanted to be sure of my child's specific trait. But then I asked myself, “What if my child was part of the Newborn Genomes Programme, then the possibility exists that other health conditions could be detected through the deep analysis of my child's genome. Would I really want to know then? What would be the psychological effect or, in some cases, the social impact of what I have to learn?” Harriet: Thank you so much, Suzalee. And I think it's just wonderful to hear about the personal impacts that this kind of work can have and thank you for bringing that to us.  Gordon, I'll hand over to you. I'd be really interested in your thoughts on this. Gordon: So my role in the Public Standing Group was to give my section of society my experiences in life to bring them together with other people, so experiences like Suzalee and the 24 other people that joined us on the study, to bring our opinions together, to bring our wide knowledge and group experiences of life. And it's important to have a wide group, because it forces us to wrestle with differences of opinion. Not everybody thinks like I do.  As a pharmacist, I can see the practical side of genomics, like pharmacogenomics, where we could use a baby's genome to predict how they'll respond to drugs over their lifetime. That's a game-changer for avoiding adverse reactions or ineffective treatments, but not everybody's sold on it. Some in our group worried about privacy, who gets this data, or ethics, like whether it's fair to sequence a baby who can't say yes or no. I get that. I don't have children, but I hear those things clearly. The most interesting bits for me, the pharmacogenomics discussion in meeting two stood out, everyone could see the tangible benefits of tailoring medicines to a person's genome, making treatments more effective, and in Meeting 5 designing our own lifetime genome resource was also fascinating. Ideas like it for public health research showed how far-reaching this could be. Some of the challenging sides of things that I came across, the toughest part was grappling with unknowns in Meeting 4, like how to share genetic info with your family without damaging relationships. Those risks felt real, and it was hard to balance them against the benefits, especially when trust from groups like minority ethnic communities is at stake. Harriet: Thank you so much, Gordon. I think from you and Suzalee it's so fascinating to hear how you were grappling, I think, with some of your personal and professional feelings about this and your deeply-held personal views and bringing those first of all out into the open, which is something that is very brave and we really respect and admire you doing that, and also then understanding that people do hold very different views about these issues. And that's why bring these issues to an engagement forum because it's important for us to hear those views and to really understand how people are considering these really tricky ethical issues. So, Suzalee, I'm wondering from your perspective how do you feel we can really be respectful towards other people's points of view? Suzalee: Yes, Harriet. In spite of the fact that we had different viewpoints on some topics discussed, every member, researcher, presenter and guests were respectful of each other's point of view. We all listened to each other with keen eyes, or sometime squinted eyes, with a hand on the chin which showed that what was being said was being processed or interpreted. All our views were recorded by our researchers for further discussion and analysis, therefore I felt heard, and I believe we all felt heard.  Harriet: Do you have any examples that you can recall from the groups where there were differing points of view and how we navigated those? Gordon: Where we had screening at age 5, but we agreed on an opt-out model, because it could help spot issues early. But some worried - psychological impacts, knowing too much too soon. But we looked at an opt-out model rather than an opt-in model because it's easier to say to somebody, “If you don't want to continue with this, opt out” rather than trying to get everybody opting in at every different age range. So, as we reach the age of 5, 10, 15, 20, whatever, it's easier to get people to opt out if they no longer want to be part of that rather than trying to get them to opt in at each stage throughout their life. Harriet: Suzannah, do you have anything to add there as a facilitator? How did you feel about bringing these different points of view together? Suzannah: Yeah, you asked about where are the tensions, where do people maybe agree a bit less or agree and hold different views, and I think what stands out is particularly…  There was an idea floated by one of the speakers about you could have your DNA data on an NHS app and then, let's say if you're in an emergency, a paramedic could have access to it or others. And that really I think brought out quite a wide range of perspectives of some in the group feeling, “You know what, anyone who has an interest, anyone that can help my health, let them have access to it as and when, completely fine,” and others took a more cautious approach saying, “This is my DNA, this is who I am, this is unique to me, my goodness, if someone, some rogue agent manages to crash the system and get hold if it goodness knows what nightmare scenario it could result in,” and so had a much more keep it locked down, keep it very limited approach to having access to your lifetime genome data and so on. So that was a really interesting example of people going, “Yep, make it free” and others going, “No, just for very specific NHS roles,” which I thought was fascinating. Harriet: Yeah, thank you so much, Suzannah. And I think it's a real tangible challenge that those of us working in this area are trying to grapple with, is finding the middle ground here with all of the challenges that this involves, for instance, our data infrastructure and the locations at which data are held. Advert: The Genomics England Research Summit is fast approaching and registration is now open! Join us for this one day in-person event on Tuesday 17 June 2025. This year's agenda dives into rare condition diagnosis, cancer genomics, pharmacogenomics, therapeutic trials, and the impact of emerging technologies. Hear from leading experts and inspirational speakers as we explore the present and future of genomics and the latest research and technology from the Genomics England research community. Keep an eye on the website, genomicsresearchsummit.co.uk for all the details and to secure your spot. Spaces are limited, so don't miss out. We'll see you at the summit! Harriet: I think this brings us really nicely onto looking at some of the ethical, legal and social issues that we need to think through when we're considering the lifetime genome.  I'm wondering if we can expand on some of these and the importance of addressing them. Gordon, would you like to give us your thoughts? Gordon: Sure, thank you. Our job was to dig into how a baby's genome could be used over the lifetime, think pharmacogenetics for better drugs, early childhood screening for conditions or carrier testing to inform family planning. We saw huge potential for individual health like catching diseases early, but also broader impacts like reducing NHS costs through prevention. Weighing the risks and benefits. The benefits like earlier diagnosis or research breakthroughs grew clearer over time with ratings rising from 4.1 to 4.7 - that's out of, I believe, a figure of 5, but risks like data breaches and family tensions over shared genetics stayed significant. We agreed the benefits could outweigh the risks but only with mitigations like transparent governance and strong security. And what are the global implications moving forward? What we discussed isn't just for the UK, it's feeding into the global conversation about newborns in genomic research. That responsibility made us think hard about equity, access, and how to build public trust. Harriet: Thank you, Gordon, I think there's so much there to unpack. And one point I think in particular that you've mentioned, and this came out really strongly as one of our main findings from these groups, was the way that a lifetime genome and the way that we might deliver that information could really impact family dynamics in ways that we might not have really thought of before or in ways that we really have to unpack further. And, Suzalee, I'd love to hear from you about this, how might diverse family dynamics need to be considered? Suzalee: Harriet, as it relates to diverse family dynamics a burning legal issue, which is then triangulated into being considered an ethical issue as well as a social issue, was the question can siblings of sperm donors be informed of life-threatening genomic discoveries? Whose responsibility is it? Will policies now have to be changed or implemented by donor banks to take into consideration the possibility of families being part of the new genomes programme? Harriet: Yeah, thank you, Suzalee. I think there's so much there that we have to unpack and in the Generation Study we're starting to look at some of those questions, but going forward into potential risks, benefits and uses of the lifetime genome, all of these new technologies around human reproduction are things that we're going to have to consider really, really carefully through an ethical and legal lens. Suzannah, I wondered if you have anything to add to these as major ethical issues that came out in these groups. Suzannah: I think, as you say, people were so fascinated by the idea of this information landing in a family, and where do you stop? Do you stop at your siblings, your direct family, the brothers and sisters of a child?  Do you go to the cousins?  Do you go to the second cousins?  It's this idea of where does family stop. And then people were really interested in thinking about who does the telling, whose job is it? And we had this fascinating conversation – I think it was in Workshop 3 – where this very stark fact was shared, which is the NHS doesn't know who your mother or your father or your siblings are; your NHS records are not linked in that way. And so that presented people with this challenge or concern that “Actually, if I get quite a serious genetic condition diagnosed in my family whose job is it to share that information, what support is there to do that and how far do we go?”  So, I think people were really fascinated and hopeful that Genomics England will really be at the vanguard of saying, “How do we as we move into an era of more genetic data being used in our healthcare, how's that managed and how's it shared?” Harriet: Yeah, thank you so much, Suzannah. So I think that what's coming out through everything that you're all saying is the huge breadth of issues that came up here. And of course we're seeing, very encouragingly, so many nods to the potential benefits, especially around things like pharmacogenomics, but we are seeing some risks.  Gordon, I wondered if you'd like to elaborate a bit further. Gordon: So, something that came up, and it divided the group quite considerably, carrier status divided us. Some saw it as reducing disease prevalence and others feared it could fuel anxiety or stigma amongst the family or other families. It showed how personal these choices are and why families need control over what they learn. Harriet: Yeah, it's a very good point, and carrier status is something that could be a conceivable use of our lifetime genome record. Suzannah? Suzannah: Just building off what Gordon was talking about, I remember there were also discussions around are we getting into a state where this is about eradication of so many different conditions, and actually how does that sit with a society that is more embracing, accommodating and supportive of people with different health needs. So, I think that was quite a big ethical discussion that was had, is, and particularly where we think about what we screen for in the future over time and so forth, people really being conscious that “Actually, where are we going with this? Are we risking demonising certain conditions and saying we don't want them on the planet anymore and what are the consequences of that?” Advert: If you're enjoying what you've heard today and you'd like to hear some more great tales from the genomics coalface, why don't you join us on the Road to Genome podcast, where our host, Helen Bethell, chats to the professionals, experts and patients involved in genomics today. In our new series, Helen talks to a fantastic array of guests including the rapping consultant, clinical geneticist Professor Julian Barwell about Fragile X Syndrome, cancer genomics and the holistic approach to his practice. A genuine mic-drop of an interview. The Road to Genome is available wherever you get your podcasts. Harriet: And I think came to a point in our final meeting where we were asking our participants, so Suzalee and Gordon and everybody else in the room, whether you might consider having a lifetime genome for yourself and what that would look like. We'd love to share your views about that, and Suzalee, I'm wondering if you can share your thoughts on that with us first. Suzalee: Definitely. I would wholeheartedly be interested in the lifetime genome programme if it was offered to me right now. I believe that the pros for me are phenomenal. I have come to terms with the thought that life is unpredictable and I have already begun to accept any health condition that comes my way. Believe you me, I have been through the stage of denial, and yes, I have frozen upon hearing health diagnoses in the past but now I believe that I am a bit wiser to accept the things that I cannot change and to prepare to face the symptoms of whatever illness I am to be dealt with or to be dealt to me. If the analysis of my genome can help me to prepare, then yes, I am going to welcome this programme with open arms. Harriet: Thank you, Suzalee. And, Gordon, how did you feel about it? Gordon: Being part of the group showed me how genomics is both thrilling and daunting.  I'd lean towards ‘yes' for a lifetime genome resource for the chance to detect conditions early, but I get why some people may say ‘no' over the data fears or ethical lines. This isn't just a science project, it's about designing a future where everyone feels included and protected. We need more voices, parents, young people, underrepresented communities, to keep shaping it in the right direction. Laws would have to be enacted regarding the storage, use and availability of genetic data. We haven't yet seen as well, how AI's complete benefits in medicine will develop over time. Harriet: Thank you so much, Gordon and Suzalee, for sharing that. And, Suzannah, I know that at the end of the Public Standing Group we generally asked all of our participants whether they would choose to have a lifetime genome, the same sort of question I've just asked Suzalee and Gordon. I wondered if you could just briefly give us an overall sense of how the Public Standing Group participants felt about that. Suzannah: Yes, so it's interesting to see that actually not everyone said, despite spending a year or almost a year discussing this, not everyone said, “Sign me up,” 6 said, “No” or “Maybe.” And the reasons they gave, this idea, “Well, all this data, could a government sell it off?  What guarantees have we got?”  So that was a reason. Somewhat of a concern also about breaches but also this idea of “What do I really want to know? Do I want to have a lifetime resource that can tell me what's going to happen next in my health?” and some say, “Let me deal with it when the symptoms start coming and that's the way I want to handle it.”  So, yeah, about 20 said, “I'd be really interested,” similar to Suzalee and Gordon, 6 on the fence or firmly, “No thanks.” Harriet: Thank you so much, Suzannah. I think your point about uncertainty there is so relevant and important to us. We see uncertainty across genomics and we're layering that here with uncertainty about futures, we're layering that with uncertainty about health. And I hope that this has served to really illustrate the magnitude of the challenge we're looking at here and I think also why for us as Genomics England this is just something we're exploring. There's so much to unpack, there's so much still to be done. In terms of our next steps for Genomics England, it feels like we could speak about this for a week but I'm going to have to wrap it up here. So, for us what are our next steps?  We hope really that as we publicise the findings of this Public Standing Group and when we start combining some of our work and looking at it in harmonisation with the work that others are doing across the world, we might be better positioned to understand the potential future directions that a lifetime genome could take. That's obviously very, very exciting because we expect to see this area of enquiry expanding significantly over the coming years.  And we're already hearing about a number of other countries who are also doing birth cohort studies like we are who might hope to use similar applications of the lifetime genome going forward. So, there's a real opportunity for us here to collaborate and it's really heart-warming that the voices of our participants in this Public Standing Group can be used to facilitate that level of engagement. For us at the Generation Study, we're already looking at the next iteration of our lifetime genomes work and we're being led by the findings of this Public Standing Group as we move forward, specifically in that we're going to be starting to take some of these emerging themes to the parents of our Generation Study babies to really find out how they would feel about them. Harriet: I'd like to extend my sincere gratitude to all for being my guests today, Suzannah Kinsella, Suzalee Blair and Gordon Bedford. Thank you so much for your time and joining me in this discussion of the lifetime genome. If you'd like to hear more content like this, which I am sure you would, please subscribe to Behind the Genes on your favourite podcast app. Thank you so much for listening. I've been your host, Dr Harriet Etheredge.  This podcast was edited by Bill Griffin at Ventoux Digital and produced by Deanna Barac for Genomics England.

Join us for a full episode all about floaty potatoes aka sea cows aka MANATEES!Find us on all the things: http://linktr.ee/bearsandbrewspodcastLinks We Discussed:https://myfwc.com/education/wildlife/manatee/viewing-guidelines/https://myfwc.com/wildlifehabitats/wildlife/manatee/myfwccomhow-to-help/https://savethemanatee.org/manatees/harassment/Sources Cited:Bates, Karl. “New Research Tracks the History of Manatees across Earth's Oceans | Duke Today.” Duke Today, 25 Aug. 2022, today.duke.edu/2022/08/new-research-tracks-history-manatees-across-earth%E2%80%99s-oceans.Canon, Cheyenne. “Mortalities Decline from Record, but Remain High.” Save the Manatee Club |, 7 Mar. 2024, savethemanatee.org/mortalities-decline-from-record-but-remain-high/.Domning, D. P. “The Earliest Known Fully Quadrupedal Sirenian.” Nature, vol. 413, no. 6856, 1 Oct. 2001, pp. 625–627, www.nature.com/articles/35098072, https://doi.org/10.1038/35098072.Foote, Andrew D, et al. “Convergent Evolution of the Genomes of Marine Mammals.” Nature Genetics, vol. 47, no. 3, 26 Jan. 2015, pp. 272–275, www.nature.com/articles/ng.3198, https://doi.org/10.1038/ng.3198.“Harassment | Save the Manatee Club.” Save the Manatee, 7 June 2023, savethemanatee.org/manatees/harassment/Jones Jr., Robert. “No Longer Endangered, Manatees Now Face Another Crisis.” University of Miami, 2 Feb. 2022, news.miami.edu/stories/2022/02/no-longer-endangered,-manatees-now-face-another-crisis.html.“Manatee Mortality Statistics.” Florida Fish and Wildlife Conservation Commission, myfwc.com/research/manatee/rescue-mortality-response/statistics/mortality/.Source. “New Research Tracks Evolution of Sea Cows | Sci.News.” Sci.News: Breaking Science News, 25 Aug. 2022, www.sci.news/biology/sirenia-evolution-11135.html.U.S. Fish & Wildlife Service. “Trichechus Manatus | U.S. Fish & Wildlife Service.” Www.fws.gov, www.fws.gov/species/manatee-trichechus-manatus. Hosted on Acast. See acast.com/privacy for more information.

When held to the scrutiny of honest questions, evolution collapses like a house of cards. What we've learned about the Genome mitigates against evolution. What we've learned about the fossil record mitigates against evolution. What we've learned about mutations and natural selection mitigates against evolution. What we've learned about the Big Bang mitigates against evolution. Kevin Swanson interviews Dr. Robert Carter on the latest book Evolution's Achilles Heel. This program includes:1. The World View in 5 Minutes with Adam McManus (Only 66% of Americans identify as Christian today, Supreme Court allows Trump's ban on transgender soldiers, Thousands joined Ireland's March for Life)2. Generations with Kevin Swanson

Gene-editing technology which makes pigs immune to a highly infectious virus, developed at Edinburgh University's Roslin Institute, has been approved for use by the US Food and Drug Administration. The virus causes a disease called PRRS or Porcine Reproductive and Respiratory Syndrome, which causes premature births in pigs as well as other painful symptoms and costs the pig industry billions. Current legislation doesn't permit its use in the UK. We speak to one of the scientists who's been working on the project for more than seven years.All week we've been taking a closer look at pulses, the dried seeds of crops like beans, lentils and peas, for both human and animal food. In the UK the peas we eat are generally frozen or fresh but dried peas are a major source of protein to millions of people around the world. Scientists at the John Innes Centre in Norwich have been working with researchers in China, the USA and France to uncover the genome of 700 different varieties of pea, from many different countries, to help develop better commercial varieties.The sudden suspension of England's biggest environmental scheme, the Sustainable Farming Incentive, earlier this year was met with horror and disbelief by farmers and environmentalists alike - we preview a special documentary which charts the transition of agricultural policy from the old EU farm subsidy system and the Common Agricultural Policy to the new 'public money for public goods' approach that we have in England today. Presenter = Caz Graham Producer = Rebecca Rooney

Jobfrust - Warum wir unseren Job wirklich kündigen ; Erste vollständige Genome vom Menschenaffen ; Lesen, Mathe, Problemlösen - Was haben wir wirklich drauf? ; Ab wann ist ein dicker Bauch ungesund? ; Generationen-Klischees: Was ist dran? ; Bangladesch - Was Monsunveränderungen für die Menschen bedeuten ; Schlangenbisse per App und KI erkennen ; Holzapfel: Apfel-Urvater vom Aussterben bedroht ; Moderation: Julia Schöning. Von WDR 5.

A new study from the Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, published in Oncotarget, reveals that the gene p53, long known as the “guardian of the genome,” may be even more powerful than previously thought. By studying it in non-cancerous human cells, researchers discovered how p53 stops risky cell growth and uncovered two new potential targets for cancer therapy. Understanding p53: The Genome's Guardian Against Cancer The p53 gene is one of the most important natural defenses our body has against cancer. When functioning properly, p53 detects damage in a cell's DNA and either stops the cell from dividing or pushes it to self-destruct. This process helps prevent potentially dangerous mutations from spreading. However, many cancers find ways to silence or mutate p53, allowing uncontrolled growth and resistance to treatments. Studying p53 in a clear and accurate way has long been a challenge. Most cancer cell models used in research already carry numerous genetic mutations, which can mask or alter how p53 truly functions. To fully understand this vital tumor-suppressing gene, scientists needed a model that closely resembled healthy, genetically stable human cells—yet could still be maintained and studied over time in the laboratory. The Study: Exploring p53 in Normal and Cancer Cell Models Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz explored p53 activity using a uniquely suitable cell line: hTERT-RPE1. These non-cancerous human cells are immortalized using telomerase, meaning they continue dividing like cancer cells, but without the chaotic mutations seen in tumors. This makes them an excellent model for studying how p53 operates in near-normal conditions. Full blog - https://www.oncotarget.org/2025/04/22/new-insights-into-p53-a-powerful-genes-role-in-cancer-therapy/ Paper DOI - https://doi.org/10.18632/oncotarget.28690 Correspondence to - Fred Bunz - fredbunz@jhmi.edu Video short - https://www.youtube.com/watch?v=Psxj3ctbTuk Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28690 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, p53, ionizing radiation, immortalized cells, ALDH3A1, NECTIN4 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode:00:46 A potato pangenomeResearchers have created a ‘pangenome' containing the genomes of multiple potato types, something they believe can help make it easier to breed and sequence new varieties. The potato's complicated genetics has made it difficult to sequence the plant's genome, but improvements in technology have allowed the team to combine sequences, allowing then to look for subtle differences in between varieties.Research Article: Sun et al.09:57 Research HighlightsHow ancient DNA analysis revealed that unusually bound medieval books are covered in sealskin, and top quarks and their antimatter counterparts are detected after nuclear smash-ups at the Large Hadron Collider.Research Highlight: Mystery of medieval manuscripts revealed by ancient DNAResearch Highlight: Top quarks spotted at mega-detector could reveal clues to early Universe12:30 The top cited twenty-first century research papersAnalysis from Nature reveals the 25 highest-cited papers published this century and explores why they are breaking records. We hear about the field that got the highest number of papers on the list, and whether any feature in the all-time top citation list.News Feature: Exclusive: the most-cited papers of the twenty-first centuryNews Feature: These are the most-cited research papers of all timeNews Feature: Science's golden oldies: the decades-old research papers still heavily cited today21:47 Briefing ChatRe-analysis of a cosmic collision shows evidence of a planet spiralling into its host star, and how shrugging off lighting strikes gives tonka bean trees an evolutionary edge.Science: Astronomers spot a planetary ‘suicide'Live Science: Tropical tree in Panama has evolved to kill its 'enemies' with lightningVote for us in this year's Webby AwardsVote for How whales sing without drowning, an anatomical mystery solvedVote for What's in a name: Should offensive species names be changed? The organisms that honour dictators, racists and criminalsVote for Cancer-busting vaccines are coming: here's how they work Hosted on Acast. See acast.com/privacy for more information.

00:46 Complete sequencing of ape genomesResearchers have sequenced the complete genomes of six ape species, helping uncover the evolutionary history of our closest relatives and offering insights into what makes humans human. The genomes of chimpanzee, bonobo, gorilla, Bornean orangutan, Sumatran orangutan and siamang have been sequenced end-to-end, filling in gaps that have long eluded researchers.Research Article: Yoo et al.News: What makes us human? Milestone ape genomes promise clues08:47 Research HighlightsHow sunflower stars are evading a mysterious epidemic, and how solar panels made of moon dust could power lunar bases.Research Highlight: Revealed: where rare and giant starfish hide from an enigmatic killerResearch Highlight: Solar cells made of Moon dust could power up a lunar base11:36 How to make a competitive laser-plasma acceleratorAfter decades of research, physicists have demonstrated that, in principle, an alternative kind of particle accelerator can work just as well as more conventional designs. Many particle accelerators that power huge experiments like the Large Hadron Collider at CERN are radio-frequency accelerators, but they are large and limited in how strong their magnetic fields can be. The new work shows that accelerators that instead use plasma to accelerate particles could be a viable alternative and could be built at much smaller scales.Research article: Winkler et al.19:55 Briefing ChatA drug that makes blood poisonous to mosquitoes, and how an AI worked out how to solve key challenges in Minecraft by ‘imagining' solutions.Science Alert: Drug For Rare Disease Turns Human Blood Into Mosquito PoisonNature: AI masters Minecraft: DeepMind program finds diamonds without being taughtVote for us in this year's Webby AwardsVote for How whales sing without drowning, an anatomical mystery solvedVote for What's in a name: Should offensive species names be changed? The organisms that honour dictators, racists and criminalsSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.

DNA sequencing is on the cusp of a major transformation, and Gilad Almogy, CEO of Ultima Genomics, is leading the charge. In this episode of FYI, ARK's Chief Futurist, Brett Winton, and Multiomics analyst Nemo Despot explore how Ultima is making whole-genome sequencing radically cheaper—driving costs down from $1,000 to just $80 per genome, with ambitions for even further reductions. Gilad shares how his background in semiconductors shaped Ultima's innovative approach, which relies on cost-efficient silicon wafers and high-throughput sequencing. The conversation also dives into the massive potential applications for low-cost sequencing, from cancer diagnostics and population genomics to AI-driven drug discovery.Key Points From This Episode:How Ultima Genomics' unique approach is slashing sequencing costsThe growing role of AI in understanding biologyWhy sequencing demand is highly elastic—cheaper data unlocks new applicationsThe future of personalized medicine and real-time cancer detectionHow population-scale genomics will transform healthcare

An interesting new study from the Geisinger health system in Pennsylvania examining if genomic screening in a large population increases the identification of disease risk prompted Raise the Line to re-release a previous episode about a textbook designed to help all medical providers understand the clinical applications of genomic testing. Genomics in the Clinic: A Practical Guide to Genetic Testing, Evaluation, and Counseling from Elsevier Science Direct dives into the use of this important tool in diagnosis and screening, indicating how individuals may respond to drug therapies, and more. “We really need to educate all healthcare providers about the practice of genetics because they're going to be involved directly or indirectly in genetic testing and conveying information about what the results mean to patients and their families,” explains co-author Dr. Ethylin Wang Jabs, enterprise chair of the Department of Clinical Genomics for Mayo Clinic. Jabs and her co-author, Dr. Antonie Kline, director of Clinical Genetics at the Harvey Institute for Human Genetics at Greater Baltimore Medical Center, chose a format that makes heavy use of case studies to help readers get a better grasp on this complicated field and they also include chapters on direct-to-consumer testing and the ethical and social implications in genomic medicine. “Any kind of potentially predictive testing can have ethical issues related to it, including insurance coverage, testing for family members, protections for minors, and more,” says Dr. Kline. Join host Caleb Furnas for an illuminating episode on an area of discussion in medicine that's growing in importance as the use of genetic testing rapidly increases. Mentioned in this episode: Genomics in the Clinic: A Practical Guide If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Cells may be the building blocks of life (and highschool biology), but who knew they were so complicated? Dr. Samantha Yammine digs into different types of cells and their functions with editorial correspondent Teresa Carey as they discuss the difficulties in defining what a cell even is. Then, Sam speaks with Dr. Sébastien Calvignac-Spencer, a pathogen evolutionary biologist about his work investigating diseases from history. Finally, some curious researchers and entrepreneurs are cultivating actual salmon meat in bioreactors so Sam investigates the process behind growing fish in a lab including the potential ecological effects of cell-cultured salmon hitting the market. Link to Show Notes HERE Follow Curiosity Weekly on your favorite podcast app to get smarter with Dr. Samantha Yammine — for free! Still curious? Get science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

Dr. Richard Sternberg speaks on his mathematical/logical work showing the difficulty of identifying genes purely with material phenomena. Source

duckDNA recently concluded its second season, which brought continued enthusiasm from hunters and several never-before-seen hybrids! On this episode, Dr. Mike Brasher is joined by conservation science assistants, Kayci Messerly and Katie Tucker, and Dr. Phil Lavretsky to share initial results from season 2 while discussing genetic mysteries uncovered through the analysis of several unique hybrid ducks. Also discussed are behind-the-scenes interactions with participating hunters and the potential future of duckDNA. Thanks to hunters for their support and participation and a special thanks to our year 2 funding partners -- Pinola Conservancy, Rice Pond Preserve, and Brian Hornung.Listen now: www.ducks.org/DUPodcastSend feedback: DUPodcast@ducks.org

On today's ID the Future from the vault, Casey Luskin continues his conversation with host Eric Anderson about the myths surrounding human origins. Luskin rebuts the popular claim that the human and chimp genomes are 98-99% similar and therefore surely resulted from Darwinian common descent. He also throws shade in the argument that humans and chimps share junk DNA similarities. The problem? So-called "pseudogenes" are turning out to have functions. Listen in as Luskin unravels this popular myth, one thread of evidence at a time. Source

Nels and Vincent explain how template switching during DNA replication is a widespread source of adaptive gene amplification. Hosts: Nels Elde and Vincent Racaniello Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiEVO Links for this episode Join the MicrobeTV Discord server Template switching and gene amplification (eLife) Timestamps by Jolene Science Picks Nels – Jeremy Berg on Bluesky – jeremymberg.bsky.social Vincent – Dickson Despommier, 84 Music on TWiEVO is performed by Trampled by Turtles Send your evolution questions and comments to twievo@microbe.tv

Spend any time in the southern Appalachian Mountains and you are bound to cross paths with Galax urceolata. This wonderful little evergreen herb seems to be at home in a variety of habitats from forest streams to granite outcrops and everywhere in between. It is also culturally significant and even suffers from poaching in some areas. Despite its place in Appalachian ecology and history, Galax holds many mysteries, especially when it comes to its genome. Join me and Dr. Shelly Gaynor as we explore the polyploidy and evolution in Galax. This episode was produced in part by Rich, Shad, Maddie, Owen, Linda, Alana, Sigma, Max, Richard, Maia, Rens, David, Robert, Thomas, Valerie, Joan, Mohsin Kazmi Photography, Cathy, Simon, Nick, Paul, Charis, EJ, Laura, Sung, NOK, Stephen, Heidi, Kristin, Luke, Sea, Shannon, Thomas, Will, Jamie, Waverly, Brent, Tanner, Rick, Kazys, Dorothy, Katherine, Emily, Theo, Nichole, Paul, Karen, Randi, Caelan, Tom, Don, Susan, Corbin, Keena, Robin, Peter, Whitney, Kenned, Margaret, Daniel, Karen, David, Earl, Jocelyn, Gary, Krysta, Elizabeth, Southern California Carnivorous Plant Enthusiasts, Pattypollinators, Peter, Judson, Ella, Alex, Dan, Pamela, Peter, Andrea, Nathan, Karyn, Michelle, Jillian, Chellie, Linda, Laura, Miz Holly, Christie, Carlos, Paleo Fern, Levi, Sylvia, Lanny, Ben, Lily, Craig, Sarah, Lor, Monika, Brandon, Jeremy, Suzanne, Kristina, Christine, Silas, Michael, Aristia, Felicidad, Lauren, Danielle, Allie, Jeffrey, Amanda, Tommy, Marcel, C Leigh, Karma, Shelby, Christopher, Alvin, Arek, Chellie, Dani, Paul, Dani, Tara, Elly, Colleen, Natalie, Nathan, Ario, Laura, Cari, Margaret, Mary, Connor, Nathan, Jan, Jerome, Brian, Azomonas, Ellie, University Greens, Joseph, Melody, Patricia, Matthew, Garrett, John, Ashley, Cathrine, Melvin, OrangeJulian, Porter, Jules, Griff, Joan, Megan, Marabeth, Les, Ali, Southside Plants, Keiko, Robert, Bryce, Wilma, Amanda, Helen, Mikey, Michelle, German, Joerg, Cathy, Tate, Steve, Kae, Carole, Mr. Keith Santner, Lynn, Aaron, Sara, Kenned, Brett, Jocelyn, Ethan, Sheryl, Runaway Goldfish, Ryan, Chris, Alana, Rachel, Joanna, Lori, Paul, Griff, Matthew, Bobby, Vaibhav, Steven, Joseph, Brandon, Liam, Hall, Jared, Brandon, Christina, Carly, Kazys, Stephen, Katherine, Manny, doeg, Daniel, Tim, Philip, Tim, Lisa, Brodie, Bendix, Irene, holly, Sara, and Margie.

The outbreak of H5N9 avian influenza occurred at a California duck farm in November 2024. Also, new research pinpoints 298 parts of the genome associated with higher risk of bipolar disorder. This could lead to better treatments.Another Strain Of Bird Flu Discovered In CaliforniaThis week, the World Organization for Animal Health reported that it had been notified by the USDA that a November outbreak of highly pathogenic avian influenza on a California duck farm was caused by a strain not before seen in the United States: H5N9. The dominant bird flu strain circulating currently, H5N1, has led to massive culling of bird flocks, has infected dairy cattle, and has killed almost 500 people around the world since 2003. The US reported its first human death from bird flu earlier this month.Experts stressed that the new strain did not itself appear to be an immediate human threat. But the rise of a new strain is troubling and points to the risk of a viral phenomenon known as “reassortment,” in which different viruses mingled in a host can sometimes exchange bits of viral code, forming new strains.SciFri's Charles Bergquist joins Flora Lichtman to talk about H5N9 and other stories from the week in science, including a spacewalk that was meant to include a search for microbes on the outside of the International Space Station, a possible positive side effect of scratching an itch, and the discovery of 66 million-year-old fossilized vomit.Understanding Bipolar Disorder Through The GenomeBipolar disorder is one of the most common mental illnesses—it affects an estimated 40 million people worldwide, about 2.8% of the population. Bipolar disorder can cause extreme mood swings, and be debilitating without treatment.In an effort to untangle the mysteries of where bipolar disorder originates, researchers studied the genomes of more than 40,000 people with the condition. When comparing these genomes to those of people without bipolar disorder, the researchers were able to pinpoint 298 different parts of the genome associated with the mental illness. With this better understanding of the genome, better, more targeted treatments for bipolar disorder may be possible.Joining Flora to talk about this research is Dr. Niamh Mullins, assistant professor of psychiatric genomics at the Icahn School of Medicine at Mount Sinai in New York.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.